1. Home
  2. WTBA vs DMAC Comparison

WTBA vs DMAC Comparison

Compare WTBA & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Bancorporation

WTBA

West Bancorporation

HOLD

Current Price

$24.39

Market Cap

375.9M

Sector

Finance

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$7.70

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WTBA
DMAC
Founded
1893
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.9M
428.6M
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
WTBA
DMAC
Price
$24.39
$7.70
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$24.00
$15.50
AVG Volume (30 Days)
43.1K
163.0K
Earning Date
04-30-2026
01-01-0001
Dividend Yield
4.05%
N/A
EPS Growth
35.21
N/A
EPS
1.92
N/A
Revenue
N/A
$500,000.00
Revenue This Year
$23.69
N/A
Revenue Next Year
$9.18
N/A
P/E Ratio
$12.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.33
$3.22
52 Week High
$26.60
$10.42

Technical Indicators

Market Signals
Indicator
WTBA
DMAC
Relative Strength Index (RSI) 47.34 39.49
Support Level $23.57 $7.46
Resistance Level $26.60 $9.01
Average True Range (ATR) 0.83 0.42
MACD -0.22 -0.08
Stochastic Oscillator 32.00 22.67

Price Performance

Historical Comparison
WTBA
DMAC

About WTBA West Bancorporation

West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America region.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: